MRNA Analysis

TradingKey - Moderna stock forecast: MRNA falls 19% in two days despite positive melanoma vaccine data, with $181.36 support now deciding whether the uptrend holds.

TradingKey - On October 22, Eastern Time, Moderna (MRNA) and Merck released Phase III melanoma trial data for Intismeran autogene, a personalized cancer vaccine. Following the announcement, Moderna's stock price plunged, closing down 20.14% at $196.31 for the day after touching an intraday low of $195.23. Although the data showed that the primary efficacy endpoints met expectations, why did the stock price crash?

On October 22 Eastern Time, Moderna (MRNA) shares tumbled as much as 25% intraday. As of press time, the stock remained down 24.24% at $186.23. Reportedly, full Phase 3 data for the melanoma vaccine jointly developed by the company and Merck (MRK) is set to be released soon, while rumors circulated in the market that the trial results were leaked in advance, though this has not been officially confirmed.

On October 9, Eastern Time, shares of Moderna (MRNA) rose by more than 10% at one point to hit a new recent high following its official inclusion in the Nasdaq 100 Index. As of press time, Moderna's gain narrowed to 5.74%, trading at $208.31. On the news front, Moderna has yet to release the full Phase 3 clinical trial results for its melanoma vaccine. Citi analyst Geoff Meacham noted that the market expects to see this data at the European Society for Medical Oncology (ESMO) Congress in Madrid later this month.

TradingKey - On Wednesday (September 30) Eastern Time, futures tied to the three major US stock indices weakened near flat lines in pre-market trading as investors await a heavy batch of US economic data releases, including ADP employment, PCE inflation, and the final reading of second-quarter GDP. The market expects US headline PCE and core PCE for August to rise by 0.5% and 0.3% month-over-month, respectively. If the data exceeds expectations, it could further reinforce expectations of continued Federal Reserve rate hikes and weigh on high-valuation tech stocks.

TradingKey - In August 2026, the upward momentum in US stocks broadened significantly. Moderna (MRNA) topped the S&P 500 constituents with a 156% gain, surging 375.9% year-to-date. Palantir (PLTR) followed closely behind, rising 51.5% in August, while enterprise software stocks as a whole extended their previous recovery.

TradingKey - MRNA closed at $142.77 after a $2B convertible-notes plan. Phase 3 melanoma success is powerful, but dilution and cash burn raise the stakes for investors.

Moderna (MRNA) announced on Thursday that it intends to conduct a private offering of $2 billion in aggregate principal amount of senior convertible notes due 2032 to qualified institutional buyers. The company also plans to grant the initial purchasers an option to purchase up to an additional $300 million aggregate principal amount of notes within a 13-day period beginning on the initial issuance date. If the option is exercised in full, the total size of the offering could reach up to $2.3 billion.

TradingKey - The U.S. Treasury Department announced market intervention measures, and the three major U.S. stock indices reversed their three-day losing streak to close higher across the board.

TradingKey - Moderna (MRNA) and Merck (MRK) announced on Wednesday that their jointly developed personalized mRNA cancer vaccine achieved positive results in a large-scale Phase 3 clinical trial. This marks the first time a personalized mRNA cancer vaccine has succeeded in a large Phase 3 clinical trial. While mRNA technology was previously best known for its application in COVID-19 vaccines, the latest results signify a major step forward toward commercialization in the field of cancer treatment. Driven by the news, Moderna's stock surged over 100% at one point in U.S. pre-market trading, while Merck's stock also traded higher.